| Literature DB >> 36198470 |
Susanne Ahlstedt Karlsson1, Ingela Henoch2, Roger Olofsson Bagge3, Catarina Wallengren4.
Abstract
OBJECTIVE: The peRson-cEntred Support Programme EndoCrine Therapy intervention is a complex intervention encompassing a person-centred support programme for patients with breast cancer being treated with endocrine therapy (ET). The aim of this study was to explore the feasibility of the trial design and patient acceptability of the intervention and outcome measures and to provide data to estimate the parameters required to design the final intervention.Entities:
Keywords: Breast tumours; QUALITATIVE RESEARCH; Quality in health care
Mesh:
Year: 2022 PMID: 36198470 PMCID: PMC9535178 DOI: 10.1136/bmjopen-2022-060946
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Demographic and clinical characteristics of the participants in the control group (n=20) and intervention group (n=21) in the peRson-cEntred Support Programme EndoCrine Therapy project
| Demographic characteristics | Control group, n=20 | Intervention group, n=21 |
| Median age, years (range) | 65 (50–85) | 66 (47–79) |
| Civil status, n (%) | ||
| Married/cohabiting | 12 (63%) | 16 (76%) |
| Single | 8 (37%) | 5 (23%) |
| Ancestral homeland, n (%) | ||
| Sweden | 16 (80%) | 18 (86%) |
| Scandinavian countries | 1 (5%) | 1 (5%) |
| Europe | 1 (5%) | 2 (10%) |
| Outside Europe | 1 (5%) | 0 (0%) |
| Education, n (%) | ||
| University | 9 (45%) | 10 (48%) |
| High school | 8 (40%) | 8 (38%) |
| Elementary school | 3 (15%) | 3 (14%) |
| Radiation therapy, n (%) | 16 (80%) | 21 (100%) |
| Tumour size, median mm (range) | 14 (4–45) | 12 (1–19) |
| Breast surgery | ||
| Mastectomy | 4 (20%) | 2 (10%) |
| Partial mastectomy | 15 (75%) | 19 (90%) |
| Axillary lymph node dissection | 1 (0.5%) | 0 (0%) |
| Tamoxifen, n (%) | 9 (45%) | 9 (43%) |
| Aromatase inhibitor, n (%) | 11 (55%) | 12 (57) |
Figure 1The care and measurement chain for the control and intervention groups. Both groups received the content in the blue area (usual care). ET, endocrine therapy.
Resource needs for the intervention
| The peRson-cEntred Support Programme EndoCrine Therapy | |
| Distributed educational material | |
| Individual educational material, part 1, n | 21 |
| Individual educational material, part 2, n | 20 |
| Individual educational material, part 3, n | 19 |
| Individual educational material, part 4, n | 19 |
| Individual educational material | |
| Information about tamoxifen or aromatase inhibitors, n | 20 |
| Additional educational material from patient needs: | |
| Complementary medicine, n | 1 |
| Sleep advice, n | 1 |
| Recommendations about internet sites: | |
| Sleep advice, n | 2 |
| Form of education and educational sessions per patient | |
| Face to face (n=0), median (range) | 0 (–) |
| Telephone (n=20), median (range) | 3 (2–4) |
| Digital (n=1), median (range) | 1 (1) |
| Length (min) per session | |
| Telephone (n=20), median (range) | 20 (5–60) |
| Digital (n=1), median (range) | 30 (30–45) |
| Length of time (weeks) between each session | |
| Telephone follow-up education sessions, weeks, median (range) | 4 (1–6) |
| Digital meeting follow-up sessions, weeks, median (range) | 4 (–) |
| Follow-up educational session | |
| Time from 1st session to 2nd session, weeks, median (range) | 2 (1–8) |
| Time from 2nd session to 3rd session, weeks, median (range) | 4 (2–8) |
| Time from 3rd session to 4th session, weeks, median (range) | 4 (2–5) |
Figure 2Baseline and 3-month difference measures in the control and intervention groups for self-efficacy and reported symptoms. MSAS, Memorial Symptom Assessment Scale; no, number of symptoms; often, how often the patient had a symptom; severe, how severe the symptom usually experienced by the patient was; distress, how much the experienced symptom distressed or bothered the patient.